Cerus Corporation (CERS)
NASDAQ:CERS
Want to see CERS full AI Analyst Report?
CERS Stock Chart & Stats
$1.92
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.92
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.15 - $3.15
Previous CloseN/A
Volume302.69K
Average Volume (3M)2.87M
Market Cap
$541.00M
Enterprise Value$678.63M
Total Cash (Recent Filing)$80.42M
Total Debt (Recent Filing)$97.36M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Jul 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding200,368,970
10 Day Avg. Volume2,556,536
30 Day Avg. Volume2,870,899
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit5.61
Enterprise Value/Ebitda-46.92
Forecast
1Y Price Target
$4.50Price Target Upside134.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$251.40M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables-driven Revenue GrowthCerus’ business model centers on recurring single-use kits and consumables tied to blood unit treatments. Sustained 24% product revenue growth and raised full-year product revenue guidance reflect deeper platform adoption, improving revenue visibility and scalable recurring cash flows over the medium term.
High-growth IFC/ISC Revenue StreamRapid IFC/ISC uptake diversifies Cerus beyond core platelet/plasma kits. Nearly 90% YoY IFC revenue growth and rising therapeutic dose equivalents indicate successful commercial conversion and an expanding addressable market, supporting durable top-line expansion and potential margin improvement as scale increases.
Improving Profitability And Operating DisciplineConsecutive positive adjusted EBITDA quarters show structural operating leverage and tighter cost control. With operating expenses declining and management forecasting continued adjusted EBITDA positivity, Cerus appears to be on a sustainable path toward GAAP profitability if revenue growth persists and margin headwinds abate.
Bears Say
Ongoing GAAP Unprofitability And Negative ROEDespite narrowing losses, Cerus remains GAAP unprofitable with negative returns on equity. Persistent net losses limit reinvestment flexibility, constrain balance-sheet strength under stress, and mean longer runway is needed before investors see sustainable GAAP earnings and durable shareholder returns.
Gross Margin Compression From Structural Cost PressuresManagement cites inflation, shipping, tariffs and FX as ongoing drivers of lower gross margins. If these structural input and logistic cost pressures persist, they will constrain operating leverage from revenue growth and make durable GAAP profitability and cash generation harder to achieve without price increases or cost savings.
Regulatory Timing Uncertainty For Red Blood Cell ProgramThe INTERCEPT RBC program is a major future revenue opportunity, but regulatory reviews and manufacturing audits create genuine timing risk. Delays to CE Mark or commercial launch would defer sizable revenue upside, extend payback periods on R&D/capacity investments, and make near-term planning lumpy.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.15 and its highest was $3.15 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $541.00M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Apr 30, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 200,368,970 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 33.99%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (134.38% Upside)
$4.50 (134.38% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $202.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 46.1%
Last 30 Days ▲ 46.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.54%
12-Months-Change
Fundamentals
Return on Equity
-15.36%
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(134.38% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.84% Insiders
12.86% Mutual Funds
36.41% Other Institutional Investors
25.74% Public Companies and
Individual Investors